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ABSTRACT  
Objective: To determine the effectiveness of probiotics in addition to traditional therapy for 
patients with ulcerative colitis (UC) using a systematic review. Methods: PubMed and Cochrane 
Library databases were queried to evaluate patient clinical trials within the past five years using 
the search terms probiotics and ulcerative colitis. Results: Three trials met inclusion criteria. 
Two of three studies found no significant improvement in their primary endpoint with probiotics. 
Yoshimatsu, et al. found that after one year 56.6% of the placebo group remained in remission, 
whereas 69.5% of the probiotic group remained in remission (p>0.05).9 Tursi, et al. found no 
significant difference (p= 0.069) in UC remission after 8 weeks of using probiotics.10 Palumbo, et 
al. did find a significant difference (p <0.05) in the UC disease activity index (UCDAI), stool 
frequency, intestinal mucosa, and rectal bleeding after two years of using a probiotic blend.11 
Conclusion: This systematic review did not show strong evidence in support of probiotic 
supplementation in UC patients. However, due to trial design and limited number of patients, a 
potential benefit to probiotics may exist. While it appears that probiotics do not pose any 
additional risk to individuals with UC, until large randomized trials are performed, we cannot 
recommend or discourage the use of probiotics. 
 
INTRODUCTION  
Ulcerative colitis (UC) is a form of inflammatory bowel disease that causes an estimated 
6 cases per 100,000 individuals annually.1 UC is characterized by relapsing-remitting episodes 
affecting the mucosal layer of the colon.2 It consistently involves the rectum and may extend 
proximally as far as the left colic flexure.2  A small subset of patients have continuing symptoms 
and are unable to arrive at complete symptomatic remission.2 UC is commonly diagnosed in 
patients aged 15-35 years old, however it can present at any age and in either gender.2  
The cause of UC is poorly understood and is still under examination. While no single 
etiology has been identified, several ideas have been studied. It is believed that many factors 
contribute to the development of UC, including a genetic predisposition, environmental factors, 
and the immune system.3 In normal hosts, phagocytic cells do not attack the enteric bacteria.3 
However, in patients with UC, phagocytes begin to mount a response to the normal microflora 
and secrete interleukin – 25, a proinflammatory cytokine, favoring a type 2 helper T cell (Th2) 
and mast cell immune response.3 This results in inflammation and injury to the mucosal layer.3   
 In contrast to the cellular level, at the organismal level there is evidence to believe that 
the enteric bacteria in individuals with UC is less diverse than in healthy patients.3 Individuals 
with inflammatory bowel disease have an increased rate of gut pathogens.3 While several 
pathogenic bacteria, such as Pectinatus, Sutterella, and Fusobacterium, are often present in UC, 
there is no evidence to prove these are causative bacteria of the disease.3  
There are three classifications of severity in UC, including: mild, moderate, and severe. 
Mild UC is characterized as intermittent rectal bleeding, associated with fewer than four episodes 
of diarrhea per day, and may also present with periods of crampy abdominal pain, tenesmus, and 
constipation. Symptoms associated with moderate UC include up to 10 episodes of diarrhea per 
day, mild abdominal pain, and a low-grade fever. Mild anemia may also be seen in moderate 
disease.2 Severe UC, however, is distinguished as greater than 10 episodes of diarrhea per day, 
severe crampy abdominal pain, fever, and anemia often requiring a blood transfusion.2 These 
patients may also suffer unintentional weight loss and develop poor nutrition.2 
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The diagnosis of UC is made based on a person having chronic diarrhea for more than 4 
weeks, evidence of inflammation on endoscopy, and chronic inflammatory changes on biopsy.2,4 
Because these criteria aren’t specific for UC, other conditions must be ruled out based on patient 
history and other lab studies.2,4,5  Patients with UC can have a wide variety of findings on 
endoscopy and biopsy.2,4  Endoscopic findings that support the diagnosis of UC include engorged, 
granular, erythematous mucosa, petechiae, spontaneous bleeding, edema, and erosions in the 
mucosa.2,4  Biopsy findings can include “crypt abscesses, crypt branching, shortening and 
disarray, and crypt atrophy” as well as others.2  
No medication can cure UC so the goal of medication therapy is to reduce symptoms and 
to induce and maintain remission.5,6  Treatment of UC largely depends on the location and 
severity of the disease, however most initial treatment for people with mild to moderate disease 
begins with the use of 5-aminosalicylic acid (5-ASA) containing medications called 
aminosalicylates.5,6 Topical and oral 5-ASA formulations, such as sulfasalazine and mesalamine, 
are available and are used for their anti inflammatory and immunosuppressive properties.6,7  Other 
medications are available for more severe cases of UC and include oral and intravenous 
corticosteroids, immunomodulators, and biologic agents.5,6  
In the addition to standard 5-ASA treatment, probiotics have been used as an adjunct 
therapy for UC.7,8  Probiotics are supplements of live microorganisms, such as Lactobacillus, 
Bifidobacterium, Saccharomyces, Escherichia coli, Enterococcus, Streptococcus, Pediococcus, 
and Leuconostoc, that are beneficial to the human gut.7,8 Probiotics are believed to decrease the 
amount of pathogenic microorganisms that are able to colonize the gut, improve the ability of the 
gut to act as a barrier, and reduce proinflammatory cytokines.8 For the aforementioned reasons, 
the use of probiotics has been studied for efficacy in the adjunct treatment of several 
gastrointestinal disorders, including UC.7,8 Three different probiotic formulations and their ability 
to aid in the prolongation of remission and reduction of symptoms in UC are reviewed here.  
 
PICO 
Population: In patients older than 13 years old with UC 
Intervention: Combination of probiotic and conventional treatment  
Control: Conventional treatment alone 
Outcome: Prolonged remission 
 
CLINICAL QUESTION 
 
In patients older than 13 years old with UC, does probiotic and conventional treatment as 
compared to conventional treatment alone prolong remission? 
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METHODS 
In September 2017 the PubMed and Cochrane Library databases were searched using the key 
terms: probiotics, ulcerative colitis, humans, within five years, and clinical trials. This search 
yielded a total of 16 articles. One additional resource was identified by searching within the 
references of one of the previously found articles. Of these 17 articles, nine were excluded 
because they either did not compare probiotics to conventional treatment, weren’t specifically 
about probiotic supplements, were not primarily about ulcerative colitis, or were meta-analyses. 
The eight remaining articles were reviewed, of which three were excluded due to failure of 
significant results or poor study design. There were three remaining articles that met all the 
necessary criteria which included: Effectiveness of probiotic therapy for the prevention of relapse 
in patients with inactive Ulcerative Colitis. Yoshimatsu et al.; Treatment of relapsing mild-to-
moderate Ulcerative Colitis with the probiotic VSL#3 as adjunctive to a standard 
pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.Tursi et al.; 
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and The long-term effects of probiotics in the therapy of Ulcerative Colitis: A clinical study. 
Palumbo et al. Figure 1 provides a diagram of this article screening process.  
 
RESULTS  
 
Study 1  
Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive 
Ulcerative Colitis. Yoshimatsu et al.9  
Study Objective: To determine if the use of probiotics in addition to conventional UC treatment 
was more effective in maintaining remission in patients with inactive UC as compared to 
conventional treatment alone over the course of 12 months.  
 
Study Design: In this randomized, double-blind, placebo-controlled study, 60 patients were 
randomly divided into one of two groups: Bio-Three probiotic tablets and identical placebo 
tablets. Both groups took three tablets of the respective preparations, three times by mouth daily 
for twelve months. Further, both groups were allowed to continue taking ongoing remission 
maintenance therapies including mesalazine and salazosulfapyridine for the entire duration of the 
study. Throughout the trial patients were monitored by assessing: exacerbation of symptoms 
monthly, and fecal samples every three months for bacterial DNA analysis and bacterial 
composition of fecal flora.   
 
Table 1. Inclusion and Exclusion Criteria for Study Participation.  
Inclusion Criteria 
 
Exclusion Criteria 
 
1. Patients in remission from UC  
2. Patients receiving outpatient treatment at 
Sakura Medical Center, Toho University, 
Japan.  
3. Age 13 and older  
4. UC Clinical Activity index of five or less 
while receiving mesalazine, 
salazosulfapyridine, or steroids 
5. No medication changes within four 
weeks of starting the trial  
 
1. Serious cardiac disease 
2. Serious renal disease 
3. Hypotension (Systolic ≤ 80 mmHg) 
4. History of shock extracorporeal 
circulation 
5. Serious infections such as sepsis or 
pneumonia 
6. Serum hemoglobin less than 10g/dL 
7. Treatments that were just recently 
begun including: leukocytapheresis, 
granulocyte adsorptive apheresis, and 
immunosuppressant therapy with 
drugs such as 6-mercaptopurine, 
azathioprine, and cyclosporine 
8. Milk allergy  
9. UC Clinical Activity Index of six or 
higher.  
10. Pregnancy  
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Results: Of the 60 randomized patients, 23 patients in the Bio-Three group, and 23 patients in 
the placebo group completed the entire one year trial. The number of patients who experienced 
relapse in the Bio-Three and placebo groups were respectively 0 vs 4 patients at 3 months 
(p=0.036), 2 vs 6 patients at 6 months (p=0.119), 5 vs 8 at 9 months (p=0.326), and 7 vs 10 
patients at 12 months (p=0.248). At the end of the 12 month study, 56.6% of the placebo group 
(12 patients), remained in remission, whereas 69.5% of the Bio-Three group (16 patients) 
maintained in remission.  
 
Number Needed to Treat (NNT): 8. The Bio-Three and placebo groups were used in order to 
calculate the NNT. The NNT demonstrates that 8 patients must be treated over 12 months in 
order for one patient to achieve remission maintenance.  
 
Critique: Strengths of this study include that it was a randomized trial, used double blinding of 
patients and researchers, and included a wide age range of patients. These features helped to 
minimize bias and could apply to a wide range of patients suffering from UC. Some weaknesses 
of this study included that it had a limited number of participants in each study group, the follow 
up was only one year, and that the results of this patient population might not be able to be 
generalized to other patient populations. Another notable weakness of the study was the high 
dropout rate of participants from 60 participants at the start to a total of 46 participants who 
completed the study. The authors explained that the dropout of 7 participants from each group, 
after randomization, was due to the fact that they met exclusion criteria such as age at onset of 
disease and use of prohibited drugs. The authors did not account for the high dropout rate in their 
analysis, even though this could affect how the results of the study can be extrapolated to 
patients in clinical practice. The results of this study were not statistically significant overall 
which may be due to having a very small sample size and only a short period of follow up used. 
If in the future, this study was done on a much larger scale with a several year follow up, results 
may show statistically significant decreases in relapse rate. Further, the population used in this 
study was from a single outpatient center in Japan, making it less likely to apply to patients in the 
US due to factors such as differing diets and environmental exposures.  
 
Study 2  
Treatment of relapsing mild-to-moderate Ulcerative Colitis with the probiotic VSL#3 as 
adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-
controlled study. Tursi et al.10  
 
Study Objective: To investigate if probiotic VSL#3 as an adjunct to standard therapy is more 
effective in treating mild-to-moderate UC compared to UC standard therapy alone.  
 
Study Design: In this multicenter, double-blind, randomized control trial, 144 patients were 
randomly assigned to receive VSL#3 probiotic mixture or placebo two times by mouth daily for 
8 weeks in addition to their mesalazine maintenance therapy for the entire duration of the study. 
The VSL#3 treatment group received sachets containing 900 billion bacteria, including strains of 
lactobacilli, bifidobacteria, and streptococcus with a daily dose of 3,600 billion bacteria per day. 
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The primary endpoints were the change in baseline in the UCDAI score (with higher scores 
indicating worse quality of life), stool frequency, intestinal mucosa, and rectal bleeding.   
 
 
Table 2. Study 2 Inclusion & Exclusion Criteria 
 
Inclusion Criteria 
 
  
Exclusion Criteria 
 
1. Greater than 18 years old 
2. Diagnosis of UC established by 
previous colonoscopy, with consistent 
histology and clinical course 
3. UC involving at least the rectosigmoid 
region; confirmed by colonoscopy 
4. Mild-to-moderate relapsing UC 
5. Relapsing episodes for < 4 weeks 
before the study 
6. Greater than or equal to> 3 UCDAI 
score at screening 
7. Use of 5-ASA at least 4 weeks before 
the study and/or azathioprine or 6-
mercaptoprine at least 3 months before 
the study 
1. Crohn’s disease or pouchitis 
2. Greater than > 8 UCDAI score 
3. Use of oral steroids within last 4 
weeks before the study 
4. Use of antibiotics within last 2 weeks 
before the study 
5. Change in dose of 5-ASA within last 4 
weeks and throughout the 8 week 
study period or a change in 
azathioprine dose within 3 months 
before the study 
6. Use of rectal 5-ASA or steroids within 
1 week beforehand or throughout 8 
week study period 
7. Use of probiotics within 2 weeks 
before the study 
8. Use of NSAIDs for 1 week before or 
through the study  
9. Pregnancy 
 
ASA, aminosalicylic acid; UC, ulcerative colitis; UCDAI, Ulcerative Colitis Disease Activity 
Index. 
 
Results:144 patients underwent randomiz 65 patients in the VSL#3 and 66 patients placebo 
group) completed the entire study. As compared with the use of mesalazine, the use of probiotic 
VSL#3 was associated with lower disease activity scores, but not with a higher incidence of 
remission. Improvement in UCDAI scores was 63.1% with VSL#3 and 40.8% with placebo ( p = 
0.010). After a followup time of 8 weeks, the remission rate was 47% with probiotic VSL#3 and 
32% with placebo, meaning remission was not significantly lower with probiotic VSL#3 than 
with placebo. While there was no significant improvement with VSL#3 in stool frequency and 
endoscopic scores, there was reduction in the frequency of rectal bleeding. Furthermore, 6 
patients in the VSL#3 group and 7 patients in the placebo group were requested to withdraw 
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from the study due to protocol violation, lost to follow up, or clinical deterioration. There were 
no adverse events reported in either group.  
 
Number Needed to Treat (NNT): 5. The VSL#3 treatment group and placebo group were used 
in order to determine the NNT. The NNT demonstrates that 5 patients must be treated over 12 
months in order for one patient to achieve decreased UC disease activity.  
 
Critique: The randomizing of assigned individuals to a study and control group is a significant 
strength of the study as it controls confounding variables. The participants and investigators were 
both blinded to the treatment, which helped to prevent bias. Groups were well balanced as there was 
no major difference in demographic characteristics (age, male-to-female ratio, and UCDAI score). The 
investigators also determined an optimal sample size for the study by using a statistical power of 
80% and a statistical significance of 95% while also anticipating subject dropouts. The follow up 
period occurred at 8 weeks, however, long term outcomes were not assessed. The study drop out 
rate was 9% (13 of 144 patients). Due to the dropout of patients, the study included intention to 
treat and per protocol outcomes.  
 
The improvement in UCDAI score of 50% or more was higher in the VSL#3 group compared to 
the placebo group (per protocol (PP) P=0.010; intention to treat (ITT) P=0.031). Significant 
results with VSL#3 are demonstrated with an improvement of three points or more in the 
UCDAI score (PP P=0.017; ITT P=0.046), whereas remission after 8 weeks (PP P=0.069; ITT 
P=0.132) did not show a significant difference. This may be due to the notion that the study was 
underpowered and included a short follow up period. Furthermore, this study was funded by 
VSL Pharmaceuticals, which may contribute to outcomes favouring the sponsor. 
 
One potential weakness in the study is the patient population was from a multicenter in Italy, 
making it more difficult to apply these results to patients in the United States due to differing 
diets and environmental factors.  
 
Study 3:  
The long-term effects of probiotics in the therapy of Ulcerative Colitis: A clinical study. Palumbo 
et al.11 
 
Study Objective: To evaluate if the long-term effects of a combination therapy of mesalazine 
plus a probiotic blend compared to mesalazine alone is more effective in treating UC.  
 
Methods: In this randomized control trial, 60 patients with moderate-to-severe UC were 
randomly assigned to receive mesalazine 1200 mg once daily or a combination of mesalazine 
1200 mg and a probiotic blend twice daily. The probiotic group received strains of Lactobacillus 
salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The primary 
endpoint was the change from baseline in in the disease activity according to the the Modified 
Mayo Disease Activity Index (MMDAI) at 24 months. The study compared the efficacy of 
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treatment by analyzing the proportion of patients who noticed clinical improvements at months 
6, 12, 18 and 24. 
 
Table 3. Study 3 Inclusion & Exclusion Criteria 
Inclusion Criteria Exclusion Criteria 
 
1. Older than 18 years old 
2. Diagnosis of UC established by 
clinical course, colonoscopy, and 
histology  
3. Moderate-to-severe disease (MMDAI 
score: 8-12)  
 
1. Steroid dependence 
2. Renal impairment  
3. Pregnancy 
4. Lactation  
5. Established low compliance  
 
 
 
Results: A total of 60 randomized patients underwent randomization (30 patients in the 
mesalazine group and 30 patients in the combination mesalazine and probiotic blend group) 
completed the two year trial. Throughout the study, patients in the combined treatment group 
achieved a significant reduction in disease activity, stool frequency, and rectal bleeding at 6 
months, as well as improvement in endoscopic findings at 18 months (p < 0.05 for each 
parameter). There were no adverse events reported in either group.  
 
Critique: The randomizing of assigned individuals to a study and control group is a significant 
strength of the study as it controls confounding variables. One strength of this study is that 
groups were well balanced as there was no significant difference in demographics (mean age and 
male-to-female ratio). Several weaknesses of this study included failure to double-blind patients 
to the control and treatment groups and the study had a limited number of patients in each group. 
Another weakness of the trial was setting up the potential for bias due to lack of blinding patients 
and researchers. In other words, patients may have become aware of their allocated treatment 
group because the placebo group received a single daily administration of mesalazine while the 
treatment group received the mesalazine plus a double daily administration of probiotic blend. 
This may have led to an increased attrition rate, demonstrated by a poor compliance rate of 85% 
among subjects. The study also failed to define several medical and statistical terms used to 
describe results and criteria for endoscopic scores. Furthermore, the researchers failed to report 
the study dropout rate, per protocol outcomes, and how the study was funded.   
 
DISCUSSION   
This review focused on the clinical significance of the use of probiotics as an adjunct 
therapy for the treatment of ulcerative colitis. The current studies demonstrate conflicting results 
on whether or not adding probiotics to the treatment regimen for UC is efficacious. Table 4 
summarizes the results of the systematically reviewed studies.  
 
Table 4. Summary of studies reviewed 
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 Study #1 
Yoshimatsu, et al.9  
Study #2 
Tursi, et al.10  
Study #3 
Palumbo, et al.11  
Objective 
 
To determine if the use 
of probiotics in addition 
to conventional UC 
treatment was more 
effective in maintaining 
remission in patients 
with inactive UC as 
compared to 
conventional treatment 
alone over the course of 
12 months.  
To investigate if 
probiotic VSL#3 as an 
adjunct to standard UC 
therapy is more 
effective in treating 
mild-to-moderate UC 
compared to standard 
therapy alone. 
 
To evaluate if the long-
term effects of a 
combination therapy of 
mesalazine plus a 
probiotic blend as 
compared to 
mesalazine alone is 
more effective in 
treating UC. 
 
 
Study Type Double-blinded RCT Double-blinded RCT RCT 
Sample Size n = 46 
(23, 23) 
n = 144 
       (71,73) 
n= 60 
(30,30) 
Study Treatments Bio-Three 
 
(Streptococcus 
faecalis, 
Clostridium butyricum, 
Bacillus mesentericus) 
VSL#3 
 
(Lactobacillus, 
Bifidobactera, 
Streptococcus 
thermophilus) 
Probiotic blend 
 
(Lactobacillus, 
Bifidobacterium 
bifidus) 
Standard Treatment Mesalazine & 
Salazosulfapyradine 
Mesalazine Mesalazine 
Follow Up Period 12 months 8 weeks 2 years 
Conclusion After 12 months, 56.6% 
of the placebo group 
(12 patients), remained 
in remission, whereas 
69.5% of the Bio-Three 
group (16 patients) 
remained in remission 
(p>0.05). 
After 8 weeks, 63.1% 
of the VSL#3 group 
reported improvement 
in >50% of UCDAI 
score, compared to 
40.8% of the placebo 
group (p<0.05). 
Furthermore, there was 
no significant 
difference in remission 
(p>0.05).  
After 2 years, there was 
a significant difference 
in MMDAI, stool 
frequency, endoscopic 
scores, and rectal 
bleeding (p<0.05). 
 
NNT NNT= 8  NNT = 5 NNT= unobtainable  
 
The three studies were similar in some aspects, however there were also distinct 
differences between them as well. One similarity was that all three studies observed the effect of 
the addition of a probiotic to a standard 5-ASA (mesalazine) treatment.9,10,11 This was important 
because the point of this research was not to see if using probiotics would replace the use of 
standard therapy, but rather to see if there were additional benefits to using the probiotics in 
combination with standard therapy. Another quality the three studies had in common was that 
they all were randomized control trials which helped to decrease bias and confounding variables 
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in each study. The studies done by Yoshimatsu, et. al. and Tursi, et al. both studied patients who 
were suffering from mild to moderate disease that was in remission at the time of study.9,10  In 
contrast, the third study observed patients that had moderate to severe disease.11 It was helpful to 
see the different impacts that the adjunct use of probiotics had on different severities of UC, but 
ultimately was a major difference in the patient population which made it difficult to make a 
final conclusion on this topic.  Tursi, et al. and Palumbo, et al. used objective symptom score 
tools as a measured outcome in the studies.10,11 Tursi, et al. used the UCDAI score, while 
Palumbo, et al. used the MMDAI score, both of which included observation of stool frequency, 
endoscopic scores, and rectal bleeding.10,11 In contrast, Yoshimatsu, et al. measured remission 
rates and fecal cluster analysis as the main outcomes of the study.9 Further differences between 
the study included use of three different probiotic formulas (Bio-Three, VSL#3, and a probiotic 
blend), patient populations and sample sizes, and length follow up periods.9,10,11  Overall these 
studies display heterogeneous results due to different outcomes studied, and differing patient 
populations.  
Each of the studies varied in their strengths and weaknesses in regards to sample size, 
patient population, and duration of the study. Yoshimatsu, et al. is a double-blinded RCT and 
enrolled patients with a wide age range.9 However, the study used a small sample size of only 46 
individuals, used a short follow up period of 12 months and as a result makes it difficult to 
conclude if the findings may be generalized to other patient populations.9  On the other hand, 
Tursi, et al. is a double-blinded RCT with a large sample size, but included the shortest follow up 
period of 8 weeks.10 Because the patient population is fairly homogeneous it is not reflective of 
the overall patient population with UC.10 The third study, Palumbo, et al. is a RCT, but failed to 
blind both subjects and investigators in order to eliminate possible bias.11 As a result of this 
potential bias and an extensive 2 year follow up period, the study reported a high dropout rate of 
patients, suggesting a major limitation in the study.11 For all of the reasons just discussed, 
Palumbo, et al. is determined to have the most limitations of the three studies while Tursi, et al. 
is believed to be the most reliable.  
The presented studies offer some evidence to support supplementation of probiotics for 
improvement of several clinical outcomes. First, in the study done by Tursi, et al., the UCDAI 
symptom score increased by at least 50% in the VSL#3 group, which was statistically 
significant.10 Also, Yoshimatsu, et al. did show some improvement, but not statistical 
significance, in maintenance of UC remission in those using probiotics compared to placebo. 
Another important result was in the Palumbo, et al. study, demonstrated significant improvement 
in UC disease activity index, stool frequency, intestinal mucosa, and rectal bleeding. So while 
not all studies show statistically significant improvements in all UC outcomes, there do not 
appear to be any adverse events associated with taking probiotics along with standard 
medications. Therefore, we do not discourage patients to take the probiotics, as they may see 
improvement in symptoms and remission with little associated risk.  
There are limitations of this systematic review due to the heterogeneity between the three 
studies with regards to the probiotic of choice, endpoints and final clinical outcomes. 
Specifically, Yoshimatsu, et al. investigated remission rates while Tursi, et al. examined UCDAI 
scores and Palumbo, et al. studied MMDAI scores.9,10,11 Both the UCDAI and MMDAI included 
similar criteria of stool frequency, rectal bleeding, endoscopic findings, and physician global 
assessment of the disease.10,11  
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Overall, additional large randomized controlled double-blind studies on the effectiveness 
of probiotics in UC is necessary to determine their potential benefits and increased remission 
rates.   
 
CONCLUSION  
This systematic review does not show strong evidence in support of probiotic 
supplementation in UC patients. However, due to trial design, limited variety of probiotic strains 
tested,  and small sample sizes, a potential benefit to probiotics may still exist. The bacterial 
composition of the probiotic blends used in these studies represent only a few of the many 
available blends in the market today. Lactobacillus and bifidobacterium species are the most 
commonly used probiotics on the market and both of these species are represented in the 
probiotic blends in the studies that are a part of this review.11 There are several commonly 
available probiotic blends that have shown benefits in human trials. Examples of the most 
effective probiotics to treat UC include Mutaflor and VSL#3, which consist of E.coli Nissle 
1917, strains of Streptococcus, Bifidobacterium and Lactobacillus.11   
It is important to consider risks associated with the use of probiotics in order to determine 
if their usage would be beneficial for all patients. Common side effects are gas and bloating, 
however, for most patients probiotic use is considered safe and associated with rare 
complications. Therefore, while it appears that probiotics do not pose any serious additional risk 
to individuals with UC, until large randomized trials are performed, we cannot recommend or 
discourage the use of probiotics. 
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